Stocktoria

Neuphoria Therapeutics Inc. NEUP

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1999-12-21

Neuphoria Therapeutics Inc. statistics & valuation

Market cap$24.7M
P / S1.6×
P / B1.3×
Net margin-2.6%
Return on equity-2.1%
Return on capital-4.6%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-2.60% 202320242025
Gross margin (%)
202320242025
Operating margin (%)
-7.20% 202320242025
Return on equity (%)
-97.10% -88.60% -2.10% 202320242025
Shares outstanding
1.49B 1.1M 2.0M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-74.90% -56.00% -1.40% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$0.02 -$18.62 -$0.23 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Operating margin-7.2%——
Net margin-2.6%——
Return on assets-1.4%-56.0%-74.9%
Return on equity-2.1%-88.6%-97.1%
Current ratio3.563.454.87

Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.